SCHEMBL1919563

SCHEMBL1919563

CCOOC(OCC)(OCC)C(OCC)(OCC)OOCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10864050 0.97
SCHEMBL17784059 0.85
SCHEMBL7484712 0.75 ALDH1A1 (0.33)
SCHEMBL27832293 0.75
SCHEMBL9353316 0.73 ALDH1A1 (0.30)
SCHEMBL6326338 0.67
SCHEMBL18650123 0.67
SCHEMBL325976 0.67
SCHEMBL18725208 0.65
SCHEMBL12125457 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230201361-A1 TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES ONCOLMMUNIN INC (US) 2023-06-29 US claimed
EP-4087587-A1 TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES ONCOIMMUNIN, INC. (US) 2022-11-16 EP claimed
JP-2002534434-A 2002-10-15 JP claimed
EP-1140966-A1 ACID STABLE BACKBONE MODIFIED END-BLOCKED NUCLEIC ACIDS AND THERAPEUTIC USES THEREOF Oligos Etc. Inc. (US) 2001-10-10 EP claimed
WO-2000040592-A1 ACID STABLE BACKBONE MODIFIED END-BLOCKED NUCLEIC ACIDS AND THERAPEUTIC USES THEREOF OLIGOS ETC. INC. (US) 2000-07-13 WO claimed
US-20230201361-A1 TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES ONCOLMMUNIN INC (US) 2023-06-29 US disclosed
US-20230065782-A1 TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES ONCOIMMUNIN INC (US) 2023-03-02 US disclosed
EP-4087587-A1 TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES ONCOIMMUNIN, INC. (US) 2022-11-16 EP disclosed
EP-3044228-B1 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH CHEMGENES CORP (US) 2021-04-07 EP disclosed
US-20190298824-A1 ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2019-10-03 US disclosed
US-10167308-B2 Highly efficient synthesis of long RNA using reverse direction approach CHEMGENES CORPORATION (US) 2019-01-01 US disclosed
WO-2017192874-A1 ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-11-09 WO disclosed
US-20060040879-A1 Chloroquine coupled nucleic acids and methods for their synthesis KOSAK KENNETH M 2006-02-23 US disclosed
EP-1202998-B1 SYNTHESIS OF STABLE QUINONE AND PHOTOREACTIVE KETONE PHOSPHORAMIDITE REAGENTS FOR SOLID PHASE SYNTHESIS OF PHOTOREACTIVE-OLIGOMER CONJUGATES EXIQON AS (DK) 2003-11-19 EP disclosed
US-6531591-B1 N,N-diisopropyl-O-(2-cyanoethyl)-O'-((anthraquinon-2 -yl)carbonylaminopropyl) phosphoramidite for example; oligonucleotides terminating in a photoreactive moiety EXIQON A/S (DK) 2003-03-11 US disclosed
US-20030045490-A1 Therapeutic antisense phosphodiesterase inhibitors OLIGOS ETC. INC. 2003-03-06 US disclosed
EP-1202998-A1 SYNTHESIS OF STABLE QUINONE AND PHOTOREACTIVE KETONE PHOSPHORAMIDITE REAGENTS FOR SOLID PHASE SYNTHESIS OF PHOTOREACTIVE-OLIGOMER CONJUGATES Exiqon A/S (DK) 2002-05-08 EP disclosed
EP-1141278-A2 THERAPEUTIC PHOSPHODIESTERASE INHIBITORS Oligos Etc. Inc. (US) 2001-10-10 EP disclosed
WO-2001004129-A1 SYNTHESIS OF STABLE QUINONE AND PHOTOREACTIVE KETONE PHOSPHORAMIDITE REAGENTS FOR SOLID PHASE SYNTHESIS OF PHOTOREACTIVE-OLIGOMER CONJUGATES EXIQON A/S (DK) 2001-01-18 WO disclosed
WO-2000040714-A2 THERAPEUTIC PHOSPHODIESTERASE INHIBITORS OLIGOS ETC. INC. (US) 2000-07-13 WO disclosed